ReviewTranslational psychiatry2025
Alcohol addiction and Alzheimer's disease: a molecular collision course.
Review in Translational psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- A Multi-Locus and Machine Learning-Based Assessment of SNCA Variants in Alzheimer's Disease.International journal of molecular sciences · 2026Article
- Timeless and Stainless Alcohol: Concentric Waves from Its Oxidative Metabolism and Related Oxidative Stress.Antioxidants (Basel, Switzerland) · 2026Review
- Alcohol-Induced Dysregulation of Hydrogen Sulfide Signaling in Alzheimer's Disease-International journal of molecular sciences · 2026Review
- Exposome influences: a multi-omics perspective on the combined toxic effects of pharmaceuticals and personal care products in Alzheimer's disease.Frontiers in toxicology · 2026Review
- Ethanol exposure and high-fat diet: assessing the neuroimmune and metabolic mechanisms in Alzheimer's disease pathology.Frontiers in neuroscience · 2026Review
- Aged female and male C57BL/6J mice have reduced alcohol self-administration and altered acute alcohol withdrawal compared to younger animals.Frontiers in aging neuroscience · 2026Article
- AQP4 Drives Gliotic Changes in an APPPS1 Mouse Model of Alzheimer's Disease.Current health sciences journalArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic alcohol consumption is increasingly recognized as a risk factor for Alzheimer's disease (AD), contributing to cognitive decline through multiple biological pathways. Excessive alcohol intake accelerates neurodegeneration by impairing the brain's ability to clear toxic proteins, disrupting neurotransmitter balance, and exacerbating inflammation and oxidative stress. These effects collectively weaken neuronal resilience, making the brain more vulnerable to AD-related damage. Emerging therapeutic strategies focus on mitigating alcohol-induced harm through neuroprotective drugs, inflammation-targeting treatments, and neurotransmitter modulators. Lifestyle-based interventions, including early abstinence, cognitive training, and precision nutrition, also show promise in reducing risk and slowing disease progression. Future research should prioritize personalized treatment approaches and novel drug delivery methods to improve outcomes for individuals affected by both conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.